Literature DB >> 11037996

The diagnostic utility of the lognormal behavior of PET standardized uptake values in tumors.

J A Thie1, K F Hubner, G T Smith.   

Abstract

UNLABELLED: A meta-analysis of data primarily from PET oncologic investigations using FDG PET was performed. Its purpose was to establish statistical features of the distributions of standardized uptake values (SUVs) as possible aids in the diagnostic process.
METHODS: We obtained 1536 values of oncologic markers from patient studies of 40 investigations in the literature. Statistical parameters were tabulated for analysis.
RESULTS: A significant observation is that, unlike skewed SUV histograms, log10SUV has Gaussian behavior, which is not uncommon for biologic quantities. This was found for SUVs of FDG and 2 amino acids as well as a few other cancer markers. A possible model for explaining this is proposed. For FDG, the SD sigma of the log10SUVs for an average cancer category was 0.23. Examining data within the framework of the model points to physiologic factors as dominating SUV variability rather than PET protocols. When data for a single cancer category were available from multiple institutions, averages, mean(SUV)s, disagree beyond chance expectations. Diagnostic utility suggestions include a universal linear relationship between sensitivity and severity, defined as SUV/mean(SUV), on semilogarithmic probability paper; a generic receiver-operating-characteristic curve for all cancers; using [log10(mean(SUVmal)/mean(SUVnorm))] divided by (sigma(mal)2 + sigma(norm)2)(1/2) as a simple diagnostic effectiveness measure; and using Gaussian log10SUVs to avoid erroneous P values.
CONCLUSION: Using the logarithms of markers, such as SUVs, several advantages stemming from their Gaussian nature can be achieved with benefits ensuing to the diagnostic process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11037996

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

1.  A weight index for the standardized uptake value in 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography.

Authors:  Joseph A Thie; Karl F Hubner; Francis P Isidoro; Gary T Smith
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

2.  A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).

Authors:  Lanell M Peterson; Brenda F Kurland; Erin K Schubert; Jeanne M Link; V K Gadi; Jennifer M Specht; Janet F Eary; Peggy Porter; Lalitha K Shankar; David A Mankoff; Hannah M Linden
Journal:  Mol Imaging Biol       Date:  2013-10-30       Impact factor: 3.488

3.  Scan-Time Corrections for 80-100-min Standardizetd Uptake Volume Ratios to Measure the 18F-AV-1451 Tracer for Tau Imaging.

Authors:  Mark He; Suzanne L Baker; Vyoma D Shah; Samuel N Lockhart; William J Jagust
Journal:  IEEE Trans Med Imaging       Date:  2018-09-17       Impact factor: 10.048

4.  Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.

Authors:  Glenn Liu; Robert Jeraj; Matt Vanderhoek; Scott Perlman; Jill Kolesar; Michael Harrison; Urban Simoncic; Jens Eickhoff; Lakeesha Carmichael; Bo Chao; Rebecca Marnocha; Percy Ivy; George Wilding
Journal:  Clin Cancer Res       Date:  2011-10-28       Impact factor: 12.531

5.  Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.

Authors:  Brenda F Kurland; Lanell M Peterson; Jean H Lee; Hannah M Linden; Erin K Schubert; Lisa K Dunnwald; Jeanne M Link; Kenneth A Krohn; David A Mankoff
Journal:  J Nucl Med       Date:  2011-09-08       Impact factor: 10.057

Review 6.  Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy.

Authors:  Paul E Kinahan; James W Fletcher
Journal:  Semin Ultrasound CT MR       Date:  2010-12       Impact factor: 1.875

7.  Practical method for radioactivity distribution analysis in small-animal PET cancer studies.

Authors:  Nikolai V Slavine; Peter P Antich
Journal:  Appl Radiat Isot       Date:  2008-06-14       Impact factor: 1.513

8.  Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.

Authors:  Christie Lin; Tyler Bradshaw; Timothy Perk; Stephanie Harmon; Jens Eickhoff; Ngoneh Jallow; Peter L Choyke; William L Dahut; Steven Larson; John Laurence Humm; Scott Perlman; Andrea B Apolo; Michael J Morris; Glenn Liu; Robert Jeraj
Journal:  J Nucl Med       Date:  2016-07-21       Impact factor: 10.057

9.  Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.

Authors:  Brenda F Kurland; Lanell M Peterson; Jean H Lee; Erin K Schubert; Erin R Currin; Jeanne M Link; Kenneth A Krohn; David A Mankoff; Hannah M Linden
Journal:  Clin Cancer Res       Date:  2016-06-24       Impact factor: 12.531

10.  Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings.

Authors:  Virendra Kumar; Kavindra Nath; Claudia G Berman; Jongphil Kim; Tawee Tanvetyanon; Alberto A Chiappori; Robert A Gatenby; Robert J Gillies; Edward A Eikman
Journal:  Clin Nucl Med       Date:  2013-03       Impact factor: 7.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.